Cargando…

Picking the Right Patient for Human Epidermal Growth Factor Receptor 3–Targeted Therapy in Platinum-Resistant Ovarian Cancer

Detalles Bibliográficos
Autores principales:	Schram, Alison M., Iasonos, Alexia, Hyman, David M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2016
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455312/ https://www.ncbi.nlm.nih.gov/pubmed/27998226 http://dx.doi.org/10.1200/JCO.2016.69.7169

Ejemplares similares

Contributions of the Epidermal Growth Factor Receptor to Acquisition of Platinum Resistance in Ovarian Cancer Cells
por: Granados, Michaela L., et al.
Publicado: (2015)

Is CA125 useful in monitoring patients with platinum-resistant ovarian cancer?
por: Rustin, G. J. S., et al.
Publicado: (2016)

Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer
por: Pujade-Lauraine, Eric
Publicado: (2013)

Epidermal Growth Factor Receptor: A Novel Target for Anticancer Treatment
por: Pandey, Manoj, et al.
Publicado: (2003)

Weekly platinum chemotherapy for recurrent ovarian cancer
por: Clamp, A, et al.
Publicado: (2002)

Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma by Targeting the Epidermal Growth Factor Receptor Combined with Gemcitabine Plus Platinum
por: Chen, Chen, et al.
Publicado: (2020)

Human epidermal growth factor receptor targeted inhibitors for the treatment of ovarian cancer
por: Bonello, Maria, et al.
Publicado: (2018)

Targeting the epidermal growth factor receptor
por: El-Rayes, B F, et al.
Publicado: (2004)

Bevacizumab combined with chemotherapy in platinum-resistant ovarian cancer: beyond the AURELIA trial
por: Lyon, Kristopher A., et al.
Publicado: (2020)

Monoclonal Antibodies against Epidermal Growth Factor Receptor in Solid Tumors
por: Saba, Nabil F., et al.
Publicado: (2012)

Epidermal growth factor receptors (EGFR) in human ovarian cancer.
por: Owens, O. J., et al.
Publicado: (1991)

The status of epidermal growth factor receptor in borderline ovarian tumours
por: Showeil, Rania, et al.
Publicado: (2016)

Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies
por: Mantia-Smaldone, Gina M, et al.
Publicado: (2010)

Targeting the Epidermal Growth Factor Receptor in Epithelial Ovarian Cancer: Current Knowledge and Future Challenges
por: Siwak, Doris R., et al.
Publicado: (2010)

Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
por: Gonzalez-Ochoa, Eduardo, et al.
Publicado: (2023)

REBECA trial: a new piece of the evidence for bevacizumab in platinum-resistant recurrent ovarian cancer
por: Lavacchi, Daniele, et al.
Publicado: (2020)

Anti-Epidermal Growth Factor Receptor (EGFR) Antibodies Overcome Resistance of Ovarian Cancer Cells to Targeted Therapy and Natural Cytotoxicity
por: Gottschalk, Nina, et al.
Publicado: (2012)

Editors' Pick: Of Horses and Genes'
por: Kayser, Manfred
Publicado: (2012)

Editors’ Pick in January 2023
por: Yang, Hee-Jin, et al.
Publicado: (2023)

Editor’s Pick in July 2023
por: Kim, Bum-Tae
Publicado: (2023)

Editors’ Pick in September 2023
por: Yang, Hee-Jin
Publicado: (2023)

Editor’s Pick in May 2023
por: Kim, Chae-Yong, et al.
Publicado: (2023)

Editors’ Pick in March 2023
por: Chung, Moonyoung
Publicado: (2023)

Editors’ Pick in November 2023
por: Chung, Moonyoung
Publicado: (2023)

Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer
por: Leamon, Christopher P, et al.
Publicado: (2013)

Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms
por: Yamaoka, Toshimitsu, et al.
Publicado: (2017)

Inhibition of Notch Signaling in Combination with Paclitaxel Reduces Platinum-Resistant Ovarian Tumor Growth
por: Groeneweg, Jolijn W., et al.
Publicado: (2014)

Effect of BRCA1 on epidermal growth factor receptor in ovarian cancer
por: Li, Da, et al.
Publicado: (2013)

Adjuvant epidermal growth factor receptor tyrosine kinase inhibitors: are we actually ready?
por: Tabbò, Fabrizio, et al.
Publicado: (2020)

Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy
por: Uno, Kaname, et al.
Publicado: (2022)

Editors’ pick: transcriptomes of 1000 genomes
por: Sajantila, Antti
Publicado: (2013)

Editors’ Pick: What a pain…, or not!
por: Kayser, Manfred
Publicado: (2014)

ULTRASONOGRAPHY: picking up the baton properly
por: CHEON, JUNG-EUN
Publicado: (2022)

Synergistic effects of combined platelet-activating factor receptor and epidermal growth factor receptor targeting in ovarian cancer cells
por: Yu, Yi, et al.
Publicado: (2014)

Exosomes as mediators of platinum resistance in ovarian cancer
por: Crow, Jennifer, et al.
Publicado: (2017)

ATR Inhibitors in Platinum-Resistant Ovarian Cancer
por: Li, Siyu, et al.
Publicado: (2022)

Ovarian Cancer—Insights into Platinum Resistance and Overcoming It
por: Havasi, Andrei, et al.
Publicado: (2023)

Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
por: McMullen, Michelle, et al.
Publicado: (2020)

Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer
por: Pchejetski, Dmitri, et al.
Publicado: (2015)

Reversing platinum resistance in ovarian cancer multicellular spheroids by targeting Bcl-2
por: Yang, Ya’nan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_cmmv6s88cf8pkt240ti7521erc